Estradiol, Progesterone, Immunomodulation, and COVID-19 Outcomes

Area of Science:

• Immunology
• Endocrinology
• Virology

Background:

• Severe COVID-19 is linked to an overactive immune response (cytokine storm) causing lung inflammation and acute respiratory distress syndrome.
• Women exhibit lower rates of severe COVID-19 outcomes and mortality compared to men, suggesting a protective role for female biology.

Purpose of the Study:

• To review the immunomodulatory and anti-inflammatory effects of 17β-estradiol (E2) and progesterone (P4).
• To explore how E2 and P4 may counteract the immune dysregulation seen in COVID-19 cytokine storms.
• To consider therapeutic strategies for mitigating COVID-19 severity by leveraging these protective factors.

Main Methods:

• Literature review of existing studies on steroid hormones and immune responses.
• Analysis of the proposed mechanisms by which E2 and P4 influence innate and adaptive immunity.
• Discussion of potential therapeutic applications in the context of COVID-19.

Main Results:

• High physiological concentrations of E2 and P4 are associated with reduced innate immune inflammation.
• These hormones promote immune tolerance and enhance antibody production.
• The combined action of E2 and P4 may help regulate the immune system to prevent or mitigate the COVID-19 cytokine storm.

Conclusions:

• Female sex hormones, E2 and P4, possess significant immunomodulatory and anti-inflammatory properties.
• These properties offer a biological explanation for the sex-based differences in COVID-19 severity.
• Harnessing the protective effects of E2 and P4 presents a potential therapeutic avenue for managing severe COVID-19.